Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
16-valent pneumococcal polysaccharide conjugate vaccine
- Development stage
- Preclinical
- Lead developer
- Shanghai Rongsheng Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 16-valent pneumococcal polysaccharide conjugate vaccine is a vaccine candidate being developed by Rongsheng Investment (Ronsen Biotech) for the prevention of pneumococcal disease caused by *Streptococcus pneumoniae*. As a conjugate vaccine, it consists of capsular polysaccharides from 16 different serotypes of the bacteria, each chemically linked to a carrier protein. This conjugation enhances the immune response, particularly in infants and young children, by inducing T-cell dependent immunity and long-term immunological memory. The vaccine is currently in the preclinical stage of development and aims to provide broader protection than existing lower-valency conjugate vaccines.
- Other names
- 16-valent Pneumococcal Polysaccharide Conjugate Vaccine16价肺炎球菌多糖结合疫苗
Beyond the preview
Go deeper on 16-valent pneumococcal polysaccharide conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 16-valent pneumococcal polysaccharide conjugate vaccine.